A drug billed by Sanofi as a successor to its blockbuster inflammation and immunology blockbuster Dupixent is being prepared for phase 3 trials in asthma – even though it missed the mark in a midstage ...

With broadcasts of the college football and NFL playoffs, as well as the men’s and women’s college basketball tournaments, many drugmakers looked to sports for advertising opportunities in Q1.

Sanofi’s next-generation experimental asthma drug failed to significantly reduce flare-ups in patients with ...

The chronic obstructive pulmonary disease (COPD) market across the seven major markets (7MM: US, France, Germany, Italy, ...

Apogee's strong financial position, with $731.1 million in cash, funds operations through Q1 2028, de-risking its ambitious ...

Tremfya achieved an impressions share of voice (SOV) of 3.35%, generating 2.1 billion total impressions. While the brand held the top spot, the total impressions dipped by 2 million from when Sanofi ...

Drilling down into subgroups of patients, Sanofi also claimed that amlitelimab demonstrated “compelling efficacy” in patients with heterogeneous inflammatory asthma. This would “potentially represent ...

A Q&A between Shawn Kwatra, M.D., professor and chair of dermatology at the University of Maryland School of Medicine, and Managed Healthcare Executive about new discoveries in chronic itch, how ...

Dupixent is already a massive seller ... It is in two phase 3 studies – AERIFY-1 and AERIFY-2 – that are due to report results next year.

Now in its 84th Five times more adults on Dupixent achieved sustained disease ... a skin disease with underlying type 2 inflammation; regulatory submissions are under review in the U.S. and ...

The RAINIER Study (NCT06496607) is an ongoing Phase IIa clinical trial investigating Solrikitug for adults with asthma. This randomized, double-blind, placebo-controlled study evaluates three dose ...

Lined up for the FDA in the coming weeks are a cell-based gene therapy for a rare skin disease and two product expansions for ...